Cancer statistics, 2018
2018/01/01 by Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · 76 citations
Medicine · Economics, Econometrics and Finance · #Global Cancer Incidence and Screening #Economic and Financial Impacts of Cancer #Colorectal Cancer Screening and Detection
paper · doi:10.3322/caac.21442
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2005-2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006-2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non-Hispanic blacks (NHBs) than non-Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.31; 95% CI, 1.29-1.32) compared with those aged ≥65 years (DRR, 1.07; 95% CI, 1.06-1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16-3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56-2.02), Kansas (DRR, 1.51; 95% CI, 1.25-1.81), Louisiana (DRR, 1.49; 95% CI, 1.38-1.60), Illinois (DRR, 1.48; 95% CI, 1.39-1.57), and California (DRR, 1.45; 95% CI, 1.38-1.54). Larger racial inequalities in young and middle-aged adults probably partly reflect less access to high-quality health care. CA Cancer J Clin 2018;68:7-30. © 2018 American Cancer Society.
Citations
Cited by
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine
- American Cancer Society guideline for diet and physical activity for cancer prevention
- Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
- Ovarian cancer statistics, 2018
- Breast cancer statistics, 2019
- Breast Cancer Statistics, 2022
- Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
- A blueprint for cancer screening and early detection: Advancing screening’s contribution to cancer control
- Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc− for Glutathione Synthesis in Lung Cancer
- Concurrent depletion of Vps37 proteins evokes ESCRT-I destabilization and profound cellular stress responses
- Ni‐induced TGF‐β signaling promotes VEGF‐a secretion via integrin β3 upregulation
- Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
- Improved bioavailability and anticancer efficacy of Hesperetin on breast cancer via a self-assembled rebaudioside A nanomicelles system
- KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
- Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia
- METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition
- Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection
- Combinational strategy for high-performance cancer chemotherapy
- BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug
- The association between cancer diagnosis, care, and outcomes in 1 million patients hospitalized for acute pulmonary embolism
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
- The Structural Model: a theory linking connections, plasticity, pathology, development and evolution of the cerebral cortex
- Projected estimates of cancer in Canada in 2020
- Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review
- Organoid models for translational pancreatic cancer research
- Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer
- How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
- Angiogenesis in pancreatic cancer: current research status and clinical implications
- Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
- LvHemB1, a novel cationic antimicrobial peptide derived from the hemocyanin of Litopenaeus vannamei, induces cancer cell death by targeting mitochondrial voltage-dependent anion channel 1
- Group-Attention Single-Shot Detector (GA-SSD): Finding Pulmonary Nodules in Large-Scale CT Images
- Hardware implementation of a quantized CNN model for early detection of skin cancer cells using hls4ml tool
- Enhancing Polyp Segmentation via Encoder Attention and Dynamic Kernel Update
- A faecal microbiota signature with high specificity for pancreatic cancer
- TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress
- Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
- Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers
- A stemness-based signature with inspiring indications in discriminating the prognosis, immune response, and somatic mutation of endometrial cancer patients revealed by machine learning
- Advanced Deep Learning Techniques for Accurate Lung Cancer Detection and Classification
- Improving the Pediatric Patient Experience During Radiation Therapy-A Children’s Oncology Group Study
- Prediction of Small Molecule Kinase Inhibitors for Chemotherapy Using Deep Learning
- Bladder Cancer in the Genomic Era
- Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
- Learning from Sparse Point Labels for Dense Carcinosis Localization in Advanced Ovarian Cancer Assessment
- Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway
- Circadian rhythm in gastrointestinal cancer: clinical applications and future perspectives
- Melanoma of unknown primary
- Medical breast ultrasound image segmentation by machine learning
- Cardioprotective effect of oleuropein in a cisplatin-induced cardiotoxicity model in rats
- Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy
- Cancer incidence and mortality in China, 2014. [europepmc]
- NCCN Guidelines Insights: Colon Cancer, Version 2.2018. [europepmc]
- Ovarian cancer statistics, 2018. [europepmc]
- Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. [europepmc]
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. [europepmc]
- A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. [europepmc]
- Epidemiology of Renal Cell Carcinoma. [europepmc]
- Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. [europepmc]
- The lung microenvironment: an important regulator of tumour growth and metastasis. [europepmc]
- Colorectal Cancer and Nutrition. [europepmc]
- Artificial intelligence in cancer imaging: Clinical challenges and applications. [europepmc]
- A Review of Curcumin and Its Derivatives as Anticancer Agents. [europepmc]
- Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. [europepmc]
- The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. [europepmc]
- Physical Activity in Cancer Prevention and Survival: A Systematic Review. [europepmc]
- Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. [europepmc]
- METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. [europepmc]
- Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. [europepmc]
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. [europepmc]
- Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. [europepmc]
- American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. [europepmc]
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. [europepmc]
- How the ageing microenvironment influences tumour progression. [europepmc]
- Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. [europepmc]
- Lung cancer immunotherapy: progress, pitfalls, and promises. [europepmc]
Related